{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:27:19Z","timestamp":1730870839840,"version":"3.28.0"},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In western industrialized nations, liver cirrhosis is the most common cause of portal hypertension. Portal hypertension is defined by a persistent increase in portal pressure &gt;7mmHg. An HVPG &gt;10mmHg defines the presence of clinically significant portal hypertension. The presence of clinically significant portal hypertension (CSPH) in patients with liver cirrhosis is a key risk factor for the transition from a compensated to a decompensated stage of the disease. CPSH can be determined invasively by measuring HPVG or noninvasively by measuring liver stiffness, platelet count and spleen stiffness. If acute decompensation manifests itself (e.g. ascites, esophageal variceal bleeding), this is associated with a significant increase in patient morbidity and mortality. Non-selective beta blockers (NSBB) are the standard medical therapy for portal hypertension in the presence of CSPH. Due to the additional \u03b11-antiadrenergic effects, carvedilol leads to a greater reduction in portal pressure compared to traditional NSBB (e.g. Propanolol). In patients with compensated liver cirrhosis, carvedilol is better than traditional NSBB at reducing the risk of variceal bleeding and the occurrence of hepatic decompensation. The early identification of CSPH and evaluation of drug therapy to reduce portal hypertension is therefore crucial to improve the prognosis of patients.<\/jats:p>","DOI":"10.1055\/a-2085-7657","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T23:54:21Z","timestamp":1710374061000},"page":"386-395","source":"Crossref","is-referenced-by-count":0,"title":["Medikament\u00f6se Therapie der portalen Hypertension"],"prefix":"10.1055","volume":"149","author":[{"given":"Anna","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Goeser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/apt.12721","article-title":"Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients","volume":"39","author":"G D\u2019Amico","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"C Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 Renewing consensus in portal hypertension","volume":"76","author":"R de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.jhep.2015.01.003","article-title":"Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments","volume":"62","author":"J Bosch","year":"2015","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jhep.2021.01.002","article-title":"Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction","volume":"75","author":"C Engelmann","year":"2021","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1055\/a-1671-9114","article-title":"Current pathophysiological concepts of acute decompensation in patients with liver cirrhosis and prognostic scores in different stages of disease","volume":"147","author":"L Sturm","year":"2022","journal-title":"Dtsch Med Wochenschr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jhep.2020.10.004","article-title":"Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality","volume":"74","author":"D Costa","year":"2021","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/cld.1031","article-title":"Hepatic Venous Pressure Gradient","volume":"17","author":"T Bochnakova","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jhep.2021.09.029","article-title":"Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?","volume":"76","author":"G Baffy","year":"2022","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jhep.2020.10.003","article-title":"Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis","volume":"74","author":"J Ferrusquia-Acosta","year":"2021","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/poh2.8","article-title":"D., Valenti L, Qi X, Zhen M-H. Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives","volume":"1","author":"TG Miao L","year":"2022","journal-title":"Port Hypertens Cirrhos"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"979","DOI":"10.14218\/JCTH.2021.00593","article-title":"Portal Hypertension in Nonalcoholic Fatty Liver Disease: From Pathogenesis to Clinical Practice","volume":"10","author":"SHH Nababan","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000647","article-title":"AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis","author":"DE Kaplan","year":"2023","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.14309\/ajg.0000000000001887","article-title":"A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease","volume":"117","author":"E Dajti","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/j.cgh.2022.09.032","article-title":"The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension","volume":"21","author":"M Jachs","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1136\/gutjnl-2012-304038","article-title":"Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol","volume":"62","author":"T Reiberger","year":"2013","journal-title":"Gut"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/liv.15559","article-title":"Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension","volume":"43","author":"L Turco","year":"2023","journal-title":"Liver Int"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"C Villanueva","year":"2019","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jhep.2022.05.021","article-title":"Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis","volume":"77","author":"C Villanueva","year":"2022","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12072-022-10416-6","article-title":"Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding","volume":"17","author":"V Arora","year":"2023","journal-title":"Hepatol Int"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/apt.17380","article-title":"Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis","volume":"57","author":"SL Gillespie","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1053\/j.gastro.2020.09.026","article-title":"Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data","volume":"160","author":"O Nicoara-Farcau","year":"2021","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s11377-022-00618-7","article-title":"Management varik\u00f6ser Blutungen","volume":"17","author":"M Praktiknjo","year":"2022","journal-title":"Die Gastroenterologie"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.cgh.2022.06.007","article-title":"Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis","volume":"21","author":"M Jachs","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/apt.17653","article-title":"Diabetes impairs the haemodynamic response to non-selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation","volume":"58","author":"R Paternostro","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.jhep.2022.12.005","article-title":"Beta-blockers in the era of precision medicine in patients with cirrhosis","volume":"78","author":"A Albillos","year":"2023","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jhep.2018.10.018","article-title":"Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices","volume":"70","author":"HY Kim","year":"2019","journal-title":"J Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s12072-020-10062-w","article-title":"Spleen stiffness measurement for assessing the response to beta-blockers therapy for high-risk esophageal varices patients","volume":"14","author":"G Marasco","year":"2020","journal-title":"Hepatol Int"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1111\/liv.14981","article-title":"Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis","volume":"41","author":"KV Danielsen","year":"2021","journal-title":"Liver Int"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1097\/HEP.0000000000000316","article-title":"Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis","volume":"77","author":"O Nicoara-Farcau","year":"2023","journal-title":"Hepatology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/liv.14042","article-title":"Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis","volume":"39","author":"E Reverter","year":"2019","journal-title":"Liver Int"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"JG Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jhep.2015.12.003","article-title":"Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats","volume":"64","author":"F Cerini","year":"2016","journal-title":"J Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/hep.29084","article-title":"The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells","volume":"65","author":"M Vilaseca","year":"2017","journal-title":"Hepatology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"E Villa","year":"2012","journal-title":"Gastroenterology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"P Schwabl","year":"2017","journal-title":"J Hepatol"},{"issue":"S 01","key":"ref38","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/S0168-8278(14)60017-9","article-title":"Effects of the FXR agonist obeticholic acid on hepatic venous pressure gradient (HVPG) in alcoholic cirrhosis: a proof of concept phase 2A study","volume":"60","author":"RM Mookerjee R","year":"2014","journal-title":"J Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/hep4.1720","article-title":"Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis","volume":"5","author":"BV John","year":"2021","journal-title":"Hepatol Commun"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1038\/s41598-017-02866-y","article-title":"Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies","volume":"7","author":"FC de Mesquita","year":"2017","journal-title":"Sci Rep"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2085-7657.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:24:31Z","timestamp":1730813071000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2085-7657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":40,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2024,3,13]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2085-7657","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"type":"print","value":"0012-0472"},{"type":"electronic","value":"1439-4413"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}